About Predictive Oncology
Predictive Oncology is a publicly listed company based in Eagan (United States) founded in 2002, and was acquired by Renovaro in January 2024. AI-based platform for cancer diagnostics and precision medicine is utilized. Predictive Oncology has raised $43 million across 9 funding rounds from investors including Draper Triangle, Longitude Capital and Adams Capital Management. The company has 24 employees. Predictive Oncology has completed 5 acquisitions, including BioDtech, Helomics and Quantitative Medicine. Its chief executive, as recorded, is Carl Schwartz. Predictive Oncology offers products and services including AI/ML Platform, 3D Tumor Models, and Clinical Testing Services. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Formation Bio, AbSci and BigHat; 3 of its 3 listed competitors have raised funding.
Company details
Predictive Oncology was founded in 2002 and is headquartered in Eagan, United States. Operations focus on the healthcare sector, where an AI-driven platform supports cancer diagnostics and precision medicine development. Multi-omics data analysis and diagnostic tools are integrated to aid treatment planning and decision-making processes. Assessment and inventory systems for personalized therapies are also maintained through this technology.
- Headquarters Eagan, United States
- Employees 24
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website predictive-oncology.com
- Social LinkedIn X Facebook
- Acquired by Renovaro (Jan 2024)
- Legal Name Predictive Oncology Inc.
- Annual Revenue$125.28 K (USD)47.72as on Dec 31, 2025
- Net Profit-$232.85 M (USD)-1808.44as on Dec 31, 2025
- EBITDA-$27.74 M (USD)-186.66as on Dec 31, 2025
- Total Equity Funding$43M (USD)
in 9 rounds
- Latest Funding Round$50.77M (USD), Post-IPO
Oct 2025
- InvestorsDraper Triangle
& 6 more
- Employee Count24
- Investments & AcquisitionsBioDtech
& 4 more
- Acquired byRenovaro
(Jan 2024)
Products & Services of Predictive Oncology
Predictive Oncology offers a comprehensive portfolio of products and services, including AI/ML Platform, 3D Tumor Models, and Clinical Testing Services.
Platform pairs AI with tumor samples to predict drug responses.
Models mimic human tumors for accurate drug response testing.
Services provide tumor drug-response and biomarker testing.
Funding Insights of Predictive Oncology
Predictive Oncology has successfully raised a total of $43M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50.77 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $43M
- Total Rounds 9
- Last Round Post-IPO — $50.77M
- First Round $43M
(Nov 2008)
- Investors Count 6
All 9 funding rounds of Predictive Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $50.77M | Post-IPO | – | – | – |
| Aug 2025 | $413,093 | Post-IPO | – | – | – |
| May 2022 | $2.3M | Post-IPO | – | – | – |
| Mar 2021 | $34.4M | Post-IPO | – | – | – |
| May 2020 | $2.2M | Post-IPO | – | – | – |
| Mar 2020 | $3.5M | Post-IPO | – | – | – |
| Aug 2013 | $14M | Post-IPO | – | – | – |
| Jun 2010 | $33.97M | Post-IPO | – | – | – |
| Nov 2008 | $43M | Private Equity Round | – | Longitude Capital |
7 investors in total: 7 institutional.
Investors in Predictive Oncology
Predictive Oncology has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Draper Triangle, Longitude Capital and Adams Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Early-stage VC investments are made in US tech companies. | acm.com | Sewickley, United States | ||
| quakerpartners.com | ||||
US focused early-stage VC firm investing in tech & life sciences start-ups | birchmerevc.com | Pittsburgh, United States | ||
US focused early stage VC investments company | 1999 | drapertriangle.com | Pittsburgh, United States | |
| tvmvc.com | ||||
Renovaro is focused on AI-driven cancer diagnostics and therapeutics. | 2023 | renovarogroup.com | Los Angeles, United States |
Investor details for Predictive Oncology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Predictive Oncology
4 people are tracked at Predictive Oncology (4 in leadership); the tracked headcount is 24.
| Name | Role | Group |
|---|---|---|
Carl Schwartz | CEO | Leadership |
Raymond F. Vennare | Chief Executive Officer | Leadership |
Mark Talton | Senior Director Of Information Technology And Cybersecurity | Leadership |
Larry Delucas | Vice President Operations | Leadership |
Complete people profiles for Predictive Oncology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Predictive Oncology
Predictive Oncology is a publicly listed company on the NASDAQ with ticker symbol POAI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Dec 2009
- Listed onNASDAQ: POAI
- Listed entityPredictive Oncology Inc.
- Exchange sectorHealth technology
- ISINUS74039M4087
- Share price$5.95 (+0.51% on the day) · 2025-12-12
- Market capitalisation$20.2M
- EPS (diluted, trailing year)$-121.02
- Volume (last session)52,548
- Analyst consensusNeutral
Financials of Predictive Oncology
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $125,280 | -$232.8M | -$27.7M |
| 2024 | $84,810 | -$12.2M | -$9.7M |
| 2023 | $1.6M | -$14.0M | -$11.4M |
| 2022 | $1.5M | -$25.7M | -$13.9M |
| 2021 | $1.4M | -$19.7M | -$11.2M |
Detailed financial statements for Predictive Oncology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Predictive Oncology
Predictive Oncology has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include BioDtech, Helomics and Quantitative Medicine.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Tumor-specific in vitro 3D models are supplied for drug development. | zpredicta.com | San Jose, United States | 2014 | Dec 2021 | •••• | |
Endotoxin detection, neutralization, and removal technologies are developed. | biodtechinc.com | Birmingham, United States | 2003 | Jul 2020 | •••• | |
Kits and services for protein solubility assessment are provided. | solublebioscience.com | Birmingham, United States | 2008 | May 2020 | •••• | |
Quantitative Medicine is a biomedical analytics and computational biology company. | qtmed.com | Pittsburgh, United States | 2012 | Jan 2020 | •••• | |
Targeted cancer therapies are developed via an AI-driven platform. | helomics.com | Pittsburgh, United States | 1995 | Jun 2018 | •••• |
Complete acquisition details for Predictive Oncology
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Predictive Oncology
10 dated milestones of Predictive Oncology across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Predictive Oncology is founded.
- Funding First funding round of $43.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Helomics.
- Acquisition Acquires Quantitative Medicine.
- Acquisition Acquires Soluble BioScience.
- Acquisition Acquires BioDtech.
- Acquisition Acquires zPREDICTA.
- Exit Acquired by Renovaro.
- Funding Latest funding round, Post-IPO, of $50.8M.
Competitors of Predictive Oncology
Predictive Oncology has 3 listed competitors in our database, 3 of them funded. They include Formation Bio, AbSci and BigHat.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| formation.bio | 2016 | New York, United States | $608.25M | AI-powered drug discovery platform for various diseases | ||
| absci.com | 2011 | Vancouver, United States | $227.56M | 256 | AI-based technology is used for recombinant protein production in therapeutics. | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | Antibody therapies are developed through machine learning and synthetic biology. |
Detailed competitors of Predictive Oncology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Predictive Oncology
The website of Predictive Oncology (predictive-oncology.com) receives about 4.3K visits a month.
- Monthly visits4.3K
▲ 11.5% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Predictive Oncology (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Predictive Oncology
Complete news archive for Predictive Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Predictive Oncology
Predictive Oncology was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Predictive Oncology is headquartered in Eagan, United States. It is registered at Eagan, Minnesota, United States.
Carl Schwartz is the CEO of Predictive Oncology, as recorded in our data.
Predictive Oncology is a funded company, having raised a total of $43M across 9 funding rounds to date. The company's 1st funding round was a Private Equity Round of $43M, raised on Nov 2008.
Predictive Oncology has 24 employees.
Annual revenue of Predictive Oncology is $125.28K as on Dec 31, 2025.
Predictive Oncology was founded in 2002 and is headquartered in Eagan, United States. Operations focus on the healthcare sector, where an AI-driven platform supports cancer diagnostics and precision medicine development. Multi-omics data analysis and diagnostic tools are integrated to aid treatment planning and decision-making processes. Assessment and inventory systems for personalized therapies are also maintained through this technology.
Predictive Oncology's top competitors include Formation Bio, BigHat and AbSci.
Predictive Oncology offers AI/ML Platform, 3D Tumor Models, and Clinical Testing Services.
Yes, Predictive Oncology is publicly traded on NASDAQ under the ticker symbol POAI.
Predictive Oncology has made 5 acquisitions, including BioDtech, Helomics, and Quantitative Medicine.
Predictive Oncology has 7 investors. Key investors include Draper Triangle, Longitude Capital, Adams Capital Management, Quaker Partners Management, and Birchmere Ventures.